Amedisys Inc has a consensus price target of $111.48 based on the ratings of 24 analysts. The high is $182 issued by Credit Suisse on April 29, 2022. The low is $85 issued by SVB Leerink on January 5, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Stephens & Co., and Deutsche Bank on March 4, 2025, February 12, 2025, and July 31, 2024, respectively. With an average price target of $101 between Stephens & Co., Stephens & Co., and Deutsche Bank, there's an implied 10.45% upside for Amedisys Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/04/2025 | Buy Now | 10.45% | Stephens & Co. | Scott Fidel 42% | $101 → $101 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
02/12/2025 | Buy Now | 10.45% | Stephens & Co. | Raj Kumar 45% | $101 → $101 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/31/2024 | Buy Now | 10.45% | Deutsche Bank | Justin Bowers49% | $101 → $101 | Downgrade | Buy → Hold | Get Alert |
07/25/2024 | Buy Now | 10.45% | Cantor Fitzgerald | Sarah James53% | $101 → $101 | Reiterates | Neutral → Neutral | Get Alert |
07/01/2024 | Buy Now | — | William Blair | Matt Larew20% | — | Downgrade | Outperform → Market Perform | Get Alert |
04/25/2024 | Buy Now | 10.45% | Cantor Fitzgerald | Sarah James53% | $101 → $101 | Reiterates | Neutral → Neutral | Get Alert |
03/26/2024 | Buy Now | — | Raymond James | John Ransom76% | — | Maintains | Market Perform | Get Alert |
03/25/2024 | Buy Now | 9.36% | RBC Capital | Ben Hendrix61% | $97 → $100 | Maintains | Outperform | Get Alert |
09/14/2023 | Buy Now | 10.45% | Cantor Fitzgerald | Sarah James53% | $100 → $101 | Maintains | Neutral | Get Alert |
07/31/2023 | Buy Now | 10.45% | TD Cowen | Gary Taylor63% | $84 → $101 | Maintains | Market Perform | Get Alert |
07/27/2023 | Buy Now | 10.45% | Credit Suisse | Jonathan Yong66% | → $101 | Reiterates | Neutral → Neutral | Get Alert |
07/06/2023 | Buy Now | 10.45% | Jefferies | Brian Tanquilut45% | $98 → $101 | Downgrade | Buy → Hold | Get Alert |
06/28/2023 | Buy Now | — | Benchmark | Bill Sutherland64% | — | Downgrade | Buy → Hold | Get Alert |
06/27/2023 | Buy Now | — | Benchmark | Bill Sutherland64% | — | Downgrade | Buy → Hold | Get Alert |
06/27/2023 | Buy Now | 10.45% | Truist Securities | David Macdonald68% | $97 → $101 | Maintains | Hold | Get Alert |
06/07/2023 | Buy Now | 6.08% | Truist Securities | David Macdonald68% | → $97 | Downgrade | Buy → Hold | Get Alert |
06/06/2023 | Buy Now | 9.36% | Cantor Fitzgerald | Sarah James53% | $91 → $100 | Maintains | Neutral | Get Alert |
06/06/2023 | Buy Now | 25.77% | Benchmark | Bill Sutherland64% | → $115 | Reiterates | Buy → Buy | Get Alert |
06/06/2023 | Buy Now | 9.36% | Credit Suisse | Jonathan Yong66% | $115 → $100 | Downgrade | Outperform → Neutral | Get Alert |
05/08/2023 | Buy Now | -8.14% | TD Cowen | Gary Taylor63% | $95 → $84 | Maintains | Market Perform | Get Alert |
05/05/2023 | Buy Now | -3.76% | Barclays | Steve Valiquette55% | $93 → $88 | Maintains | Equal-Weight | Get Alert |
05/04/2023 | Buy Now | 6.08% | Truist Securities | David Macdonald68% | $115 → $97 | Maintains | Buy | Get Alert |
05/04/2023 | Buy Now | 12.64% | Stephens & Co. | Scott Fidel71% | → $103 | Reiterates | → Equal-Weight | Get Alert |
04/21/2023 | Buy Now | -4.86% | Cantor Fitzgerald | Sarah James53% | → $87 | Initiates | → Neutral | Get Alert |
04/13/2023 | Buy Now | 25.77% | Truist Securities | David Macdonald68% | $130 → $115 | Maintains | Buy | Get Alert |
03/14/2023 | Buy Now | 25.77% | Benchmark | Bill Sutherland64% | → $115 | Reiterates | → Buy | Get Alert |
03/14/2023 | Buy Now | 12.64% | Stephens & Co. | Scott Fidel71% | → $103 | Reiterates | → Equal-Weight | Get Alert |
03/13/2023 | Buy Now | 1.71% | Barclays | Steve Valiquette55% | → $93 | Initiates | → Equal-Weight | Get Alert |
02/27/2023 | Buy Now | 25.77% | Credit Suisse | Jonathan Yong66% | → $115 | Reiterates | → Outperform | Get Alert |
02/21/2023 | Buy Now | 21.39% | RBC Capital | Ben Hendrix61% | $114 → $111 | Maintains | Outperform | Get Alert |
02/16/2023 | Buy Now | 3.89% | Stephens & Co. | Scott Fidel71% | → $95 | Reiterates | → Equal-Weight | Get Alert |
02/16/2023 | Buy Now | 25.77% | Benchmark | Mark Miller65% | $120 → $115 | Maintains | Buy | Get Alert |
02/13/2023 | Buy Now | 31.23% | Benchmark | Bill Sutherland64% | → $120 | Reiterates | → Buy | Get Alert |
01/25/2023 | Buy Now | 31.23% | Benchmark | Bill Sutherland64% | $135 → $120 | Maintains | Buy | Get Alert |
01/23/2023 | Buy Now | 25.77% | Credit Suisse | Jonathan Yong66% | $140 → $115 | Maintains | Outperform | Get Alert |
01/19/2023 | Buy Now | 36.7% | Oppenheimer | Colin Rusch53% | $145 → $125 | Maintains | Outperform | Get Alert |
01/05/2023 | Buy Now | -7.04% | SVB Leerink | Whit Mayo67% | $96 → $85 | Maintains | Market Perform | Get Alert |
11/11/2022 | Buy Now | 15.92% | Stephens & Co. | Scott Fidel71% | $122 → $106 | Maintains | Equal-Weight | Get Alert |
11/01/2022 | Buy Now | 4.99% | SVB Leerink | Whit Mayo67% | $116 → $96 | Maintains | Market Perform | Get Alert |
11/01/2022 | Buy Now | 33.42% | Stephens & Co. | Scott Fidel71% | $105 → $122 | Maintains | Equal-Weight | Get Alert |
10/31/2022 | Buy Now | 52.01% | RBC Capital | Frank Morgan46% | $165 → $139 | Maintains | Outperform | Get Alert |
10/28/2022 | Buy Now | 37.8% | Barclays | Sarah James53% | $154 → $126 | Maintains | Overweight | Get Alert |
10/28/2022 | Buy Now | 14.83% | Stephens & Co. | Scott Fidel71% | $120 → $105 | Maintains | Equal-Weight | Get Alert |
10/28/2022 | Buy Now | 42.17% | Truist Securities | David Macdonald68% | $140 → $130 | Maintains | Buy | Get Alert |
10/28/2022 | Buy Now | 58.57% | Oppenheimer | Michael Wiederhorn63% | $175 → $145 | Maintains | Outperform | Get Alert |
10/27/2022 | Buy Now | — | Raymond James | John Ransom76% | — | Downgrade | Outperform → Market Perform | Get Alert |
10/24/2022 | Buy Now | 80.45% | Deutsche Bank | Justin Bowers49% | $175 → $165 | Maintains | Buy | Get Alert |
10/05/2022 | Buy Now | 53.11% | Truist Securities | David Macdonald68% | $150 → $140 | Maintains | Buy | Get Alert |
10/03/2022 | Buy Now | 47.64% | Benchmark | Bill Sutherland64% | $165 → $135 | Maintains | Buy | Get Alert |
08/02/2022 | Buy Now | 3.89% | UBS | Andrew Mok58% | $145 → $95 | Downgrade | Neutral → Sell | Get Alert |
08/01/2022 | Buy Now | 53.11% | Raymond James | John Ransom76% | $180 → $140 | Maintains | Outperform | Get Alert |
07/29/2022 | Buy Now | 68.42% | Barclays | Sarah James53% | $181 → $154 | Maintains | Overweight | Get Alert |
07/28/2022 | Buy Now | 80.45% | Benchmark | Bill Sutherland64% | $175 → $165 | Maintains | Buy | Get Alert |
07/14/2022 | Buy Now | 64.04% | Truist Securities | David Macdonald68% | $175 → $150 | Maintains | Buy | Get Alert |
06/29/2022 | Buy Now | 39.98% | Stifel | Tao Qiu44% | → $128 | Initiates | → Hold | Get Alert |
06/21/2022 | Buy Now | 11.55% | B of A Securities | Joanna Gajuk66% | $145 → $102 | Downgrade | Neutral → Underperform | Get Alert |
06/21/2022 | Buy Now | 91.38% | Deutsche Bank | Justin Bowers49% | $210 → $175 | Maintains | Buy | Get Alert |
06/21/2022 | Buy Now | 91.38% | Truist Securities | David Macdonald68% | $200 → $175 | Maintains | Buy | Get Alert |
06/21/2022 | Buy Now | 36.7% | Stephens & Co. | Scott Fidel71% | $155 → $125 | Maintains | Equal-Weight | Get Alert |
06/21/2022 | Buy Now | 17.02% | SVB Leerink | Whit Mayo67% | $117 → $107 | Maintains | Market Perform | Get Alert |
05/27/2022 | Buy Now | 27.95% | SVB Leerink | Whit Mayo67% | $131 → $117 | Maintains | Market Perform | Get Alert |
04/29/2022 | Buy Now | 99.04% | Credit Suisse | A.J. Rice70% | $181 → $182 | Maintains | Outperform | Get Alert |
04/29/2022 | Buy Now | 96.85% | Raymond James | John Ransom76% | $200 → $180 | Maintains | Outperform | Get Alert |
04/29/2022 | Buy Now | 43.26% | SVB Leerink | Whit Mayo67% | $162 → $131 | Maintains | Market Perform | Get Alert |
The latest price target for Amedisys (NASDAQ:AMED) was reported by Stephens & Co. on March 4, 2025. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 10.45% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Amedisys (NASDAQ:AMED) was provided by Stephens & Co., and Amedisys reiterated their equal-weight rating.
There is no last upgrade for Amedisys
The last downgrade for Amedisys Inc happened on July 31, 2024 when Deutsche Bank changed their price target from $101 to $101 for Amedisys Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $101.00 to $101.00. The current price Amedisys (AMED) is trading at is $91.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.